This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
GeoVax says the FDA's approval of Replimune's intratumoral therapy validates the strategy behind its own Gedeptin — using localized tumor destruction to prime cold tumors for checkpoint inhibitor response. Clinical data in JCI Insight supports the approach. #Oncology #Immunotherapy
2026-08-11T14:00:04.683Z